EIB EXPECTED TO FUNNEL EURO 200 MILLION TO TEVA
December 1st, 2008
BY KEITH NUTHALL
THE EUROPEAN Investment Bank (EIB) has drawn up a plan to lend Euro 200 million to what it calls "the largest generic pharmaceutical company", thought to be Israel-based Teva Pharmaceutical Industries. The loan is to finance research and development for new generics and biosimilars, including clinical trials and regulatory approval procedures, backing privately backed work in Hungary, the Netherlands, Britain and Israel. This, said an EIB memorandum "will be carried out within existing facilities, mostly in the EU and Israel, ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.